Attorney Docket No. GMX-002 Appl. No. 10/724,532 Amdt. Dated February 13, 2006 Reply to Final Office Action of December 14, 2005

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of the Claims:

- 1. (Currently amended) An isolated polypeptide comprising the amino acid sequence of SEQ ID NO:1 with at least two amino acid substitutions at [a] two locations selected from the group consisting of Leu-9, Asn-12, Phe-13, Ile-16, Leu-20, Ile-26, Val-27, and Leu-30.
- 2. (Previously amended) The isolated polypeptide of claim 1, wherein the substitutions are with a non-hydrophobic amino acid.
- 3. (Previously amended) The isolated polypeptide of claim 1, wherein the substitutions are with an amino acid selected from the group consisting of alanine and glycine.
- 4. (Previously amended) The isolated polypeptide of claim 3, wherein substitutions are made at Leu-9 and Asn-12.
- 5. (Previously amended) The isolated polypeptide of claim 1, wherein the polypeptide is linked to a compound to be targeted to a sarco(endo)plasmic region of a cell.
- 6. (Previously amended) The isolated polypeptide of claim 1, wherein the polypeptide is linked to a macromolecule to be targeted to a sarco(endo)plasmic region of a cell.
- 7. (Previously amended) The isolated polypeptide of claim 4, wherein the polypeptide is linked to a macromolecule or compound to be targeted to a sarco(endo)plasmic region of a cell.
- 8. (Previously amended) An isolated polypeptide comprising the amino acid sequence of SEQ ID NO:2.

Attorney Docket No. GMX-002 Appl. No. 10/724,532 Amdt. Dated February 13, 2006 Reply to Final Office Action of December 14, 2005

- 9. (Previously amended) The isolated polypeptide of claim 8, wherein the polypeptide is linked to a compound to be targeted to a sarco(endo)plasmic region of a cell.
- 10. (Previously amended) The isolated polypeptide of claim 8, wherein the polypeptide is linked to a macromolecule to be targeted to a sarco(endo)plasmic region of a cell.
- 11. (Previously amended) An isolated nucleic acid comprising a nucleotide sequence encoding the polypeptide sequence of SEQ ID NO:1 with at least two codon substitutions encoding an amino acid substitution at two amino acid locations selected from the group consisting of Leu-9, Asn-12, Phe-13, Ile-16, Leu-20, Ile-26, Val-27, and Leu-30.
- 12. (Previously amended) The isolated nucleic acid of claim 11, wherein the codon substitutions encodes a non-hydrophobic amino acid
- 13. (Previously amended) The isolated nucleic acid of claim 11, wherein the codon substitutions encodes an amino acid selected from the group consisting of alanine and glycine.
- 14. (Previously amended) The isolated nucleic acid of claim 11, wherein the nucleotide sequence is linked to a second nucleotide sequence encoding a protein to be targeted to a sarco(endo)plasmic region of a cell.
- 15. (Previously amended) An isolated nucleic acid comprising a nucleotide sequence selected from nucleotide sequences represented by SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6.
- 16. (Currently amended) The isolated nucleic acid of claim 15, wherein when the nucleotide sequence is selected from SEO ID NO:3 and SEO ID NO:5, the nucleotide sequence is linked to a second nucleotide sequence encoding a protein to be targeted to a sarco(endo)plasmic region of a cell; [or] and wherein when the nucleotide sequence is selected from SEQ ID NO:4 and SEQ ID NO:6, the nucleotide sequence is linked to [a compliment of] a [second] third nucleotide

Attorney Docket No. GMX-002 Appl. No. 10/724,532 Amdt. Dated February 13, 2006 Reply to Final Office Action of December 14, 2005

sequence, wherein the third nucleotide sequence is a compliment of a polynucleotide that encodes [encoding] a protein to be targeted to a sarco(endo)plasmic region of a cell.

17. - 20. Cancelled.

- 21. (New) A method for targeting a compound or a macromolecule to the sarco(endo)plasmic region of a cell, the method comprising the steps of:
- (1) providing an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:1 with at least one amino acid substitution at a location selected from the group consisting of Leu-9, Asn-12, Phe-13, Ile-16, Leu-20, Ile-26, Val-27, and Leu-30;
- (2) linking the polypeptide to a compound or macromolecule to provide a linked compound or linked macromolecule;
- (3) administering the polypeptide-linked compound or polypeptide-linked macromolecule to cells.
- 22. (New) The method of claim 21, wherein the substitution is made with a non-hydrophobic amino acid.
- 23. (New) The method of claim 21, wherein the substitution is made with an amino acid selected from the group consisting of alanine and glycine.
- 24. (New) The method of claim 21, wherein substitutions are made at Leu-9 and Asn-12.